

Timothy Cloughesy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6538088/publications.pdf>

Version: 2024-02-01

189
papers

21,548
citations

21215

62
h-index

11282

141
g-index

192
all docs

192
docs citations

192
times ranked

22936
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial. <i>Neuro-Oncology</i> , 2023, 25, 123-134.	0.6	150
2	Characterization of cognitive function in survivors of diffuse gliomas using resting-state functional MRI (rs-fMRI). <i>Brain Imaging and Behavior</i> , 2022, 16, 239-251.	1.1	5
3	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 585-593.	3.2	18
4	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602.	3.2	67
5	Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors. <i>Neuro-Oncology</i> , 2022, 24, 1020-1028.	0.6	12
6	Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib. <i>Neuro-Oncology</i> , 2022, 24, 770-778.	0.6	28
7	Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI. <i>Scientific Reports</i> , 2022, 12, 1078.	1.6	5
8	Prognostic value of <i>O</i> ⁶ -methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas. <i>Neuro-Oncology Advances</i> , 2022, 4, vda030.	0.4	7
9	Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. <i>Neuro-Oncology Advances</i> , 2022, 4, vda025.	0.4	18
10	Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3510-3519.	0.8	7
11	Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type <i>MGMT</i> Promoter Methylated Glioblastoma With Measurable Disease. <i>Frontiers in Oncology</i> , 2022, 12, 849993.	1.3	1
12	Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. <i>Neuro-Oncology</i> , 2022, 24, 1219-1229.	0.6	9
13	Radiographic Response Assessment Strategies for Early-Phase Brain Trials in Complex Tumor Types and Drug Combinations: from Digital "Flipbooks" to Control Systems Theory. <i>Neurotherapeutics</i> , 2022, 19, 1855-1868.	2.1	1
14	Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life. <i>CNS Oncology</i> , 2022, 11, CNS84.	1.2	2
15	Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study. <i>Cancers</i> , 2022, 14, 2520.	1.7	2
16	Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation. <i>Journal of Neuro-Oncology</i> , 2022, 159, 509-518.	1.4	8
17	Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials. <i>Neuro-Oncology</i> , 2021, 23, 189-198.	0.6	11
18	Voxelwise and Patientwise Correlation of ¹⁸ F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-Naïve Diffuse Gliomas with Different Molecular Subtypes. <i>Journal of Nuclear Medicine</i> , 2021, 62, 319-325.	2.8	13

#	ARTICLE	IF	CITATIONS
19	Relative oxygen extraction fraction (rOEF) MR imaging reveals higher hypoxia in human epidermal growth factor receptor (EGFR) amplified compared with non-amplified gliomas. <i>Neuroradiology</i> , 2021, 63, 857-868.	1.1	7
20	Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab082.	0.4	2
21	FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab017.	0.4	6
22	Dopamine Receptor Antagonists, Radiation, and Cholesterol Biosynthesis in Mouse Models of Glioblastoma. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1094-1104.	3.0	16
23	Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?. <i>Neuro-Oncology</i> , 2021, 23, 347-349.	0.6	4
24	Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET. <i>Cancer Imaging</i> , 2021, 21, 27.	1.2	13
25	Preferential tumor localization in relation to 18F-FDOPA uptake for lower-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2021, 152, 573-582.	1.4	2
26	Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1022-1029.	1.2	5
27	Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4491-4499.	3.2	112
28	Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. <i>Nature Communications</i> , 2021, 12, 4031.	5.8	21
29	Abstract LB125: Pharmacokinetics of paxalisib in phase 2 clinical study in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promoter status. , 2021, , .		0
30	Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 395-403.	1.0	2
31	Leveraging external data in the design and analysis of clinical trials in neuro-oncology. <i>Lancet Oncology, The</i> , 2021, 22, e456-e465.	5.1	53
32	Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. <i>Neuro-Oncology</i> , 2021, 23, 356-375.	0.6	59
33	Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. <i>Cell Reports</i> , 2021, 37, 109957.	2.9	38
34	ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. <i>Nature Cancer</i> , 2021, 2, 1372-1386.	5.7	39
35	Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. <i>Nature Communications</i> , 2021, 12, 6938.	5.8	93
36	âœAerobic glycolytic imagingâœof human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imaging. <i>NeuroImage: Clinical</i> , 2021, 32, 102882.	1.4	8

#	ARTICLE	IF	CITATIONS
37	A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). <i>Neuro-Oncology</i> , 2020, 22, 705-717.	0.6	47
38	Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study. <i>Neuro-Oncology</i> , 2020, 22, 694-704.	0.6	23
39	Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa124.	0.4	5
40	Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study. <i>Scientific Reports</i> , 2020, 10, 11922.	1.6	23
41	Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma. <i>JAMA Oncology</i> , 2020, 6, 1939.	3.4	84
42	Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas. <i>Journal of Neuro-Oncology</i> , 2020, 149, 337-346.	1.4	5
43	Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma. <i>Scientific Reports</i> , 2020, 10, 14819.	1.6	13
44	Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden. <i>Neurosurgery</i> , 2020, 87, 931-938.	0.6	14
45	Ivosidenib in Isocitrate Dehydrogenase 1 Mutated Advanced Glioma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3398-3406.	0.8	167
46	Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. <i>Neuro-Oncology</i> , 2020, 22, 1262-1275.	0.6	109
47	Diffusion MRI changes in the anterior subventricular zone following chemoradiation in glioblastoma with posterior ventricular involvement. <i>Journal of Neuro-Oncology</i> , 2020, 147, 643-652.	1.4	5
48	Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. <i>Neuro-Oncology</i> , 2020, 22, 1425-1438.	0.6	37
49	Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2020, 147, 135-145.	1.4	12
50	First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 1820-1828.	3.2	54
51	Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1799-1809.	1.3	17
52	The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 11085-11096.	3.3	33
53	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	0.6	543
54	Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. <i>Neuro-Oncology</i> , 2020, 22, 1822-1830.	0.6	23

#	ARTICLE	IF	CITATIONS
55	Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 3135-3144.	3.2	7
56	THER-06. THERAPEUTIC EFFICACY OF RRV-MEDIATED PRODRUG ACTIVATOR GENE THERAPY IN CLINICAL TRIALS OF RECURRENT HIGH-GRADE GLIOMA AND IN MURINE ORTHOTOPIC MODELS OF INTRACEREBRAL GLIOMA AND INTRACEREBELLAR MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, iii472-iii472.	0.6	0
57	CTNI-38. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED (ND) OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE. <i>Neuro-Oncology</i> , 2020, 22, ii51-ii51.	0.6	1
58	Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series. <i>CNS Oncology</i> , 2019, 8, CNS35.	1.2	7
59	Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. <i>Cell Metabolism</i> , 2019, 30, 525-538.e8.	7.2	130
60	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. <i>Neuro-Oncology</i> , 2019, 21, 1498-1508.	0.6	49
61	Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1565-1576.	1.9	11
62	Somatostatin Receptor Ligand Therapy—A Potential Therapy for Neurocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2395-2402.	1.8	7
63	Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T. <i>American Journal of Neuroradiology</i> , 2019, 40, 979-986.	1.2	24
64	Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data. <i>Clinical Cancer Research</i> , 2019, 25, 4993-5001.	3.2	57
65	To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs. <i>Neuro-Oncology</i> , 2019, 21, 1239-1249.	0.6	16
66	Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. <i>Neuro-Oncology</i> , 2019, 21, 1184-1196.	0.6	28
67	SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation. <i>Journal of Neuro-Oncology</i> , 2019, 142, 423-434.	1.4	8
68	Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. <i>Scientific Reports</i> , 2019, 9, 2846.	1.6	32
69	Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 741-750.	0.8	103
70	pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 587-595.	1.4	28
71	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <i>Nature Medicine</i> , 2019, 25, 477-486.	15.2	932
72	ACTR-66. A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS. <i>Neuro-Oncology</i> , 2019, 21, vi28-vi29.	0.6	17

#	ARTICLE	IF	CITATIONS
73	ATIM-49 (LTBK-01). AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE [®]) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM). <i>Neuro-Oncology</i> , 2019, 21, vi283-vi283.	0.6	14
74	Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation. <i>Clinical Cancer Research</i> , 2019, 25, 1913-1922.	3.2	57
75	The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?. <i>Neuro-Oncology</i> , 2018, 20, 1034-1043.	0.6	100
76	18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study. <i>Journal of Neuro-Oncology</i> , 2018, 139, 399-409.	1.4	32
77	Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. <i>Neuro-Oncology</i> , 2018, 20, 1525-1535.	0.6	15
78	Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1411-1418.	0.6	24
79	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1240-1250.	0.6	64
80	Platform trials arrive on time for glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 723-725.	0.6	14
81	Simultaneous p^H-sensitive and oxygen-sensitive ^{MRI} of human gliomas at 3 ^T using multi-echo amine proton chemical exchange saturation transfer spin- and gradient echo echo-planar imaging (^{CEST}SAGE-EPI). <i>Magnetic Resonance in Medicine</i> , 2018, 80, 1962-1978.	1.9	38
82	Improved Spatiotemporal Resolution of Dynamic Susceptibility Contrast Perfusion MRI in Brain Tumors Using Simultaneous Multi-Slice Echo-Planar Imaging. <i>American Journal of Neuroradiology</i> , 2018, 39, 43-45.	1.2	15
83	Phase 2 and biomarker study of trebananib, an angiopoietin-1 blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. <i>Cancer</i> , 2018, 124, 1438-1448.	2.0	38
84	Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. <i>Neuro-Oncology</i> , 2018, 20, 674-686.	0.6	364
85	D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced <i>MIR148A</i> Promoter Methylation. <i>Molecular Cancer Research</i> , 2018, 16, 947-960.	1.5	8
86	Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. <i>Neuro-Oncology</i> , 2018, 20, 457-471.	0.6	44
87	Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. <i>Neuro-Oncology</i> , 2018, 20, 249-258.	0.6	78
88	Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. <i>Journal of Neuro-Oncology</i> , 2018, 136, 79-86.	1.4	21
89	Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 295-305.	3.2	68
90	Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. <i>Clinical Cancer Research</i> , 2018, 24, 737-743.	3.2	154

#	ARTICLE	IF	CITATIONS
91	Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas. <i>Brain Tumor Pathology</i> , 2018, 35, 1-9.	1.1	12
92	Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients. <i>Scientific Reports</i> , 2018, 8, 14429.	1.6	22
93	Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 139, 651-659.	1.4	25
94	Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. <i>Neuro-Oncology</i> , 2018, 20, 1383-1392.	0.6	135
95	Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas?. <i>Neuro-Oncology</i> , 2018, 20, 1144-1144.	0.6	3
96	A gene expression signature predicts recurrence-free survival in meningioma. <i>Oncotarget</i> , 2018, 9, 16087-16098.	0.8	26
97	Human <i>TERT</i> promoter mutation enables survival advantage from <i>MGMT</i> promoter methylation in <i>IDH1</i> wild-type primary glioblastoma treated by standard chemoradiotherapy. <i>Neuro-Oncology</i> , 2017, 19, now189.	0.6	65
98	Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 132, 181-188.	1.4	16
99	Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 132, 351-358.	1.4	34
100	Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, now287.	0.6	128
101	Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. <i>Neurotherapeutics</i> , 2017, 14, 307-320.	2.1	294
102	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. <i>Neuro-Oncology</i> , 2017, 19, 625-635.	0.6	137
103	mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antipporter xCT. <i>Molecular Cell</i> , 2017, 67, 128-138.e7.	4.5	147
104	Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 134, 177-188.	1.4	118
105	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O ⁶ -Methylguanine-DNA Methyltransferase Biomarker Analyses. <i>Journal of Clinical Oncology</i> , 2017, 35, 343-351.	0.8	110
106	Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. <i>Nature Medicine</i> , 2017, 23, 1342-1351.	15.2	79
107	Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10220-10225.	3.3	79
108	NovoTTF: where to go from here?. <i>Neuro-Oncology</i> , 2017, 19, 605-608.	0.6	14

#	ARTICLE	IF	CITATIONS
109	Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. <i>Clinical Cancer Research</i> , 2017, 23, 5745-5756.	3.2	53
110	Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats. <i>Experimental and Molecular Pathology</i> , 2017, 103, 87-93.	0.9	7
111	Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. <i>Journal of Neuro-Oncology</i> , 2017, 134, 357-362.	1.4	22
112	Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. <i>Neuro-Oncology</i> , 2017, 19, 89-98.	0.6	68
113	NCMP-01. SEIZURE CONTROL AFTER INITIAL PRESENTATION IN IDH MUTATED GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2017, 19, vi135-vi136.	0.6	1
114	GENE-41. EPIGENETIC DOWN-REGULATION OF THE METALLOTHIONEIN FAMILY IN ISOCITRATE DEHYDROGENASE (IDH) MUTANT GLIOMAS. <i>Neuro-Oncology</i> , 2017, 19, vi101-vi101.	0.6	0
115	Adult Glioblastoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2402-2409.	0.8	561
116	PD-1 blockade enhances the vaccination-induced immune response in glioma. <i>JCI Insight</i> , 2016, 1, .	2.3	128
117	Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. <i>Cancer Cell</i> , 2016, 29, 563-573.	7.7	140
118	Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. <i>Neuro-Oncology</i> , 2016, 18, 1313-1318.	0.6	39
119	Large-scale assessment of the gliomasphere model system. <i>Neuro-Oncology</i> , 2016, 18, 1367-1378.	0.6	82
120	Biomarkers in NOA-04: another piece to the puzzle. <i>Neuro-Oncology</i> , 2016, 18, 1467-1469.	0.6	4
121	An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. <i>Cancer Cell</i> , 2016, 30, 683-693.	7.7	237
122	Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2016, 130, 571-579.	1.4	39
123	Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3T. <i>NMR in Biomedicine</i> , 2016, 29, 1563-1576.	1.6	51
124	Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. <i>Science Translational Medicine</i> , 2016, 8, 341ra75.	5.8	158
125	Contrast-enhancing tumor growth dynamics of preoperative, treatment-naïve human glioblastoma. <i>Cancer</i> , 2016, 122, 1718-1727.	2.0	47
126	Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 1229-1237.	1.9	27

#	ARTICLE	IF	CITATIONS
127	Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 17.	2.0	15
128	The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. <i>Clinical Cancer Research</i> , 2016, 22, 575-581.	3.2	62
129	Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. <i>Neuro-Oncology</i> , 2016, 18, 557-564.	0.6	432
130	Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping. <i>NeuroImage: Clinical</i> , 2015, 9, 617-624.	1.4	23
131	SURG-09RESULTS OF A DOSE ESCALATION TRIAL OF TOCA 511 WITH TOCA FC IN RECURRENT HGG UNDERGOING REPEAT RESECTION. <i>Neuro-Oncology</i> , 2015, 17, v216.1-v216.	0.6	0
132	NIMG-24HIGH SPATIOTEMPORAL DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI USING MULTIBAND ECHOPLANAR IMAGING (MB-EPI). <i>Neuro-Oncology</i> , 2015, 17, v158.4-v159.	0.6	70
133	Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. <i>Molecular Cancer</i> , 2015, 14, 189.	7.9	38
134	Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients. <i>PLoS ONE</i> , 2015, 10, e0141334.	1.1	52
135	The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. <i>Neuro-Oncology</i> , 2015, 17, 1589-1598.	0.6	57
136	Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2166-2175.	0.8	112
137	GENO-30DISTINCT GENE EXPRESSION PROFILE THAT IS NOT A KNOWN SURVIVAL PREDICTOR IN TUMORS FROM LONG-TERM HIGH GRADE GLIOMA SURVIVORS TREATED WITH A RETROVIRAL REPLICATING VECTOR ENCODING YEAST CYTOSINE DEAMINASE. <i>Neuro-Oncology</i> , 2015, 17, v98.2-v98.	0.6	0
138	IMCT-05COMBINABILITY OF TOCA FC AND TOCA 511 WITH CHEMOTHERAPY AND TARGETED AGENTS. <i>Neuro-Oncology</i> , 2015, 17, v108.1-v108.	0.6	0
139	A novel bicompartmental mathematical model of glioblastoma multiforme. <i>International Journal of Oncology</i> , 2015, 46, 825-832.	1.4	5
140	Patient-specific characterization of the invasiveness and proliferation of low-grade gliomas using serial MR imaging and a mathematical model of tumor growth. <i>Oncology Reports</i> , 2015, 33, 2883-2888.	1.2	5
141	Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9406-9411.	3.3	96
142	2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. <i>Cell Metabolism</i> , 2015, 22, 508-515.	7.2	190
143	Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. <i>Molecular Imaging and Biology</i> , 2015, 17, 434-442.	1.3	28
144	Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI. <i>Clinical Cancer Research</i> , 2015, 21, 4373-4383.	3.2	27

#	ARTICLE	IF	CITATIONS
145	Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. <i>Nature Reviews Cancer</i> , 2015, 15, 302-310.	12.8	305
146	pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. <i>Neuro-Oncology</i> , 2015, 17, 1514-1524.	0.6	96
147	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. <i>Neuro-Oncology</i> , 2015, 17, 1188-98.	0.6	346
148	Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma. <i>CNS Oncology</i> , 2015, 4, 247-256.	1.2	16
149	Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. <i>Neuro-Oncology</i> , 2015, 17, 180-188.	0.6	28
150	Diffusion MRI Characteristics after Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. <i>Tomography</i> , 2015, 1, 37-43.	0.8	12
151	Patient-Specific Metrics of Invasiveness Reveal Significant Prognostic Benefit of Resection in a Predictable Subset of Gliomas. <i>PLoS ONE</i> , 2014, 9, e99057.	1.1	89
152	Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. <i>Neuro-Oncology</i> , 2014, 16, 414-420.	0.6	82
153	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). <i>Neuro-Oncology</i> , 2014, 16, vii36-vii47.	0.6	41
154	Pros and cons of current brain tumor imaging. <i>Neuro-Oncology</i> , 2014, 16, vii2-vii11.	0.6	56
155	BI-10 * pH-WEIGHTED MRI IN HUMAN GLIOMAS. <i>Neuro-Oncology</i> , 2014, 16, v25-v25.	0.6	0
156	Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial. <i>Radiology</i> , 2014, 271, 200-210.	3.6	150
157	Glioblastoma: From Molecular Pathology to Targeted Treatment. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2014, 9, 1-25.	9.6	427
158	Bevacizumab plus Radiotherapyâ€™Temozolomide for Newly Diagnosed Glioblastoma. <i>New England Journal of Medicine</i> , 2014, 370, 709-722.	13.9	2,078
159	The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings. <i>Clinical Biochemistry</i> , 2014, 47, 258-266.	0.8	198
160	Tumor-Suppressive miR148a Is Silenced by CpG Island Hypermethylation in <i>IDH1</i>-Mutant Gliomas. <i>Clinical Cancer Research</i> , 2014, 20, 5808-5822.	3.2	30
161	Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. <i>Neuro-Oncology</i> , 2014, 16, 1541-1546.	0.6	12
162	Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. <i>Cancer Biology and Medicine</i> , 2014, 11, 255-63.	1.4	44

#	ARTICLE	IF	CITATIONS
163	PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. <i>PET Clinics</i> , 2013, 8, 201-217.	1.5	8
164	EGFR Mutation-Induced Alternative Splicing of Max Contributes to Growth of Glycolytic Tumors in Brain Cancer. <i>Cell Metabolism</i> , 2013, 17, 1000-1008.	7.2	130
165	Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy. <i>Neuro-Oncology</i> , 2013, 15, 382-390.	0.6	38
166	Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2012, 14, 333-343.	0.6	74
167	¹⁸ F-FDOPA and ¹⁸ F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. <i>Neuro-Oncology</i> , 2012, 14, 1079-1089.	0.6	99
168	Differential Sensitivity of Glioma- versus Lung Cancer-Specific EGFR Mutations to EGFR Kinase Inhibitors. <i>Cancer Discovery</i> , 2012, 2, 458-471.	7.7	304
169	Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. <i>Lancet Oncology</i> , The, 2012, 13, e196-e204.	5.1	49
170	Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: A radiographic study in 358 de novo human glioblastomas. <i>NeuroImage</i> , 2012, 59, 908-916.	2.1	128
171	Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. <i>Journal of Neuro-Oncology</i> , 2012, 108, 491-498.	1.4	149
172	The Impact of Recent Data on the Optimization of Standards of Care in Newly Diagnosed Glioblastoma. <i>Seminars in Oncology</i> , 2011, 38, S11-S20.	0.8	16
173	Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases. <i>Journal of Neuro-Oncology</i> , 2011, 102, 477-484.	1.4	68
174	Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?. <i>Neuro-Oncology</i> , 2011, 13, 1118-1124.	0.6	100
175	Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2011, 13, 1151-1161.	0.6	69
176	Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 1963-1972.	0.8	3,222
177	Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 4733-4740.	0.8	2,219
178	Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. <i>Neuro-Oncology</i> , 2008, 10, 162-170.	0.6	362
179	Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma. <i>PLoS Medicine</i> , 2008, 5, e8.	3.9	499
180	The prevalence of favorable PTEN and MGMT biomarker status in 66 glioblastomas. <i>FASEB Journal</i> , 2008, 22, 706.16.	0.2	0

#	ARTICLE	IF	CITATIONS
181	Phase II Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Either Receiving or Not Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 3651-3656.	0.8	151
182	¹⁸ F-FDOPA PET imaging of brain tumors: comparison study with ¹⁸ F-FDG PET and evaluation of diagnostic accuracy. <i>Journal of Nuclear Medicine</i> , 2006, 47, 904-11.	2.8	293
183	Content Based Image Retrieval for MR Image Studies of Brain Tumors. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006, , .	0.5	0
184	Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. <i>Cancer</i> , 2003, 97, 2381-2386.	2.0	110
185	Irinotecan Treatment for Recurrent Malignant Glioma Using an Every-3-Week Regimen. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 204-208.	0.6	39
186	Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. <i>Journal of Neuro-Oncology</i> , 2000, 50, 215-226.	1.4	251
187	Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma. <i>Magnetic Resonance in Medicine</i> , 1999, 41, 2-7.	1.9	150
188	Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma. , 1999, 41, 2.		2
189	Topographic mapping of somatosensory evoked potentials helps identify motor cortex more quickly in the operating room. <i>Brain Topography</i> , 1992, 5, 53-58.	0.8	24